Instituto Rosenbusch Past Earnings Performance
Past criteria checks 3/6
Instituto Rosenbusch has been growing earnings at an average annual rate of 55.2%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 50.3% per year. Instituto Rosenbusch's return on equity is 22.1%, and it has net margins of 19.7%.
Key information
55.2%
Earnings growth rate
55.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 50.3% |
| Return on equity | 22.1% |
| Net Margin | 19.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Instituto Rosenbusch makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5,081 | 1,002 | 955 | 0 |
| 31 Mar 24 | 5,175 | 999 | 1,036 | 0 |
| 31 Dec 23 | 4,528 | 563 | 1,156 | 0 |
| 30 Sep 23 | 6,721 | -244 | 1,904 | 0 |
| 30 Jun 23 | 6,787 | -526 | 1,817 | 0 |
| 31 Mar 23 | 5,138 | -199 | 1,422 | 0 |
| 31 Dec 22 | 4,276 | -25 | 1,054 | 0 |
| 30 Sep 22 | 2,550 | 59 | 685 | 0 |
| 30 Jun 22 | 1,892 | 19 | 503 | 0 |
| 31 Mar 22 | 1,668 | 29 | 440 | 0 |
| 31 Dec 21 | 1,523 | -38 | 397 | 0 |
| 30 Sep 21 | 1,266 | -56 | 282 | 0 |
| 30 Jun 21 | 1,224 | -24 | 255 | 0 |
| 31 Mar 21 | 1,009 | -38 | 224 | 0 |
| 31 Dec 20 | 843 | -26 | 197 | 0 |
| 30 Sep 20 | 746 | -47 | 204 | 0 |
| 30 Jun 20 | 662 | -63 | 243 | 0 |
| 31 Mar 20 | 585 | -114 | 209 | 0 |
| 31 Dec 19 | 561 | -121 | 211 | 0 |
| 30 Sep 19 | 360 | -119 | 132 | 0 |
| 30 Jun 19 | 363 | -42 | 81 | 0 |
| 31 Mar 19 | 350 | -3 | 91 | 0 |
| 31 Dec 18 | 299 | 1 | 79 | 0 |
| 30 Sep 18 | 481 | -17 | 139 | 0 |
| 30 Jun 18 | 359 | -50 | 121 | 0 |
| 31 Mar 18 | 293 | -53 | 98 | 0 |
| 31 Dec 17 | 274 | -48 | 90 | 0 |
| 30 Sep 17 | 163 | 11 | 52 | 0 |
| 30 Jun 17 | 174 | 11 | 56 | 0 |
| 31 Mar 17 | 171 | 11 | 51 | 0 |
| 31 Dec 16 | 167 | 10 | 46 | 0 |
| 30 Sep 16 | 186 | 9 | 51 | 0 |
| 30 Jun 16 | 167 | 6 | 48 | 0 |
| 31 Mar 16 | 150 | 1 | 44 | 0 |
| 31 Dec 15 | 135 | -1 | 39 | 0 |
| 30 Sep 15 | 107 | -10 | 30 | 0 |
| 30 Jun 15 | 109 | -1 | 29 | 0 |
| 31 Mar 15 | 106 | -4 | 29 | 0 |
| 31 Dec 14 | 108 | 8 | 28 | 0 |
| 30 Sep 14 | 106 | 8 | 26 | 0 |
| 30 Jun 14 | 98 | 0 | 25 | 0 |
| 31 Mar 14 | 94 | 4 | 24 | 0 |
| 31 Dec 13 | 85 | -9 | 23 | 0 |
Quality Earnings: ROSE has a large one-off gain of ARS315.3M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: ROSE became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ROSE has become profitable over the past 5 years, growing earnings by 55.2% per year.
Accelerating Growth: ROSE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ROSE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.8%).
Return on Equity
High ROE: ROSE's Return on Equity (22.1%) is considered high.